
PLRX Pliant Therapeutics, Inc.Stock Price & Overview
Stock Price & Overview
$1.38
PLRX Stock Price
Quant Ranking
PLRX Analysis










PLRX News
Latest Headlines
Ratings Summary
People Also Follow
Similar to PLRX
ETFs Holding PLRX
PLRX Company Profile
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company’s lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
PLRX Revenue
PLRX Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
PLRX Ownership
PLRX Peers
Risk
Technicals
Investor Presentations
PLRX SEC Filings
Press Releases
PLRX Income Statement
PLRX Balance Sheet
PLRX Cash Flow Statement
PLRX Long Term Solvency
Discover More
You may be interested in: